Page 1

argenx argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update - Completion of enrollment expected by year - end for ADAPT - SC and ADVANCE ( IV ) trials of efgartigimod ; topline data for both trials expected in first half of 2022 - Introduced " argenx 2025 " vision during R & D Day to highlight commitment to patients and science and outline path to becoming global , integrated immunology leader July 29 , 2021 - Management to host conference call today at 2:30 pm CEST ( 8:30 am ET ) - Breda , the Netherlands argenx ( Euronext & Nasdaq : ARGX ) , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer , today announced its half year 2021 financial results and provided a second quarter business update and outlook for the remainder of the year . " The first half of 2021 has been marked by clinical , financial and regulatory achievements for argenx . As we look toward 2022 , we believe we are well - positioned to build on the impressive progress we have made with our first - in - class FcRn antagonist , efgartigimod . We are expanding our commercial organization to reach patients living with generalized myasthenia gravis this year and expect that these investments will benefit us in the future and support our growing , differentiated pipeline , " said Tim Van Hauwermeiren , Chief Executive Officer of argenx . " Beyond myasthenia gravis , we are expanding the breadth of efgartigimod into our fifth and sixth indications , myositis and bullous pemphigoid , and simultaneously investing in potential scientific breakthroughs through our Immunology Innovation Program ( IIP ) . Our first - in - class C2 inhibitor , ARGX - 117 , emerged from the IIP and has the potential to be our next pipeline - in - a - product opportunity . Collectively , the demonstrated execution this year supports our ' argenx 2025 ' vision and brings us closer than ever to becoming a global , integrated , immunology company , " concluded Mr. Van Hauwermeiren . SECOND QUARTER 2021 AND RECENT BUSINESS UPDATE During its July 20th R & D Day , argenx introduced its long - term vision to becoming a global , integrated immunology organization . The ‘ argenx 2025 ' vision includes the following goals : - - Efgartigimod being globally available to patients across its three expanding commercial franchises in neuromuscular diseases , hematology and dermatology Efgartigimod either being commercially available or in clinical development in 15 active indications Progress across broader immunology pipeline with ARGX - 117 in multiple late - stage trials and ARGX - 119 demonstrating proof - of - concept Investment in continued expansion of differentiated pipeline through its Immunology Innovation Program ( IIP ) , generating one new asset into pipeline each year